Mark Breidenbach
Stock Analyst at Oppenheimer
(1.65)
# 3,112
Out of 4,711 analysts
63
Total ratings
30.65%
Success rate
-0.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $19.83 | +51.29% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.87 | +595.19% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.60 | +962.50% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $18.48 | +414.07% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $2.00 | +1,150.00% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $1.01 | +890.10% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $12 | $0.92 | +1,210.76% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $4 | $0.20 | +1,870.44% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.53 | +357.52% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.80 | +1,677.78% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $0.20 | +6,400.00% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $7.38 | +103.25% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.42 | +8,350.70% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $0.98 | +2,244.31% | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $225 → $195 | $0.17 | +116,109.77% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2,700 | $8.50 | +31,664.71% | 3 | Dec 13, 2019 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $19.83
Upside: +51.29%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.87
Upside: +595.19%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.60
Upside: +962.50%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $18.48
Upside: +414.07%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $2.00
Upside: +1,150.00%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $1.01
Upside: +890.10%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $0.92
Upside: +1,210.76%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.20
Upside: +1,870.44%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.53
Upside: +357.52%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.80
Upside: +1,677.78%
Mar 3, 2023
Maintains: Outperform
Price Target: $15 → $13
Current: $0.20
Upside: +6,400.00%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $7.38
Upside: +103.25%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.42
Upside: +8,350.70%
Apr 26, 2021
Initiates: Outperform
Price Target: $23
Current: $0.98
Upside: +2,244.31%
May 12, 2020
Maintains: Outperform
Price Target: $225 → $195
Current: $0.17
Upside: +116,109.77%
Dec 13, 2019
Upgrades: Outperform
Price Target: $2,700
Current: $8.50
Upside: +31,664.71%